Product logins

Find logins to all Clarivate products below.


Gastroesophageal Cancer – Current Treatment – Current Treatment: Physician Insights – Gastroesophageal Cancer (US)

The gastroesophageal cancer therapy market is gaining a lot of traction. In the HER2-positive segment, trastuzumab-based regimens, with or without Keytruda, continue to dominate. Meanwhile, the HER2-negative setting is on the brink of a significant transformation. Immune checkpoint inhibitors such as Opdivo and Keytruda have achieved unparalleled penetration into all populations and lines of therapy. The FDA’s anticipated restriction of PD-1 inhibitors to PD-L1-expressing tumors, coupled with the approval of the first-in-class claudin 18.2 inhibitor Vyloy, will further reshape market dynamics in this space.

QUESTIONS ANSWERED

  • What are the treatment rates for gastroesophageal cancer in the various settings and lines of therapy?
  • What is Vyloy’s impact on the HER2-negative gastroesophageal cancer market?
  • What are the leading therapies in the treatment of HER2-positive gastroesophageal cancer?
  • What do surveyed oncologists consider the main drivers of and key obstacles to the uptake of select therapies?

PRODUCT DESCRIPTION

Through survey data from U.S. physicians, Current Treatment: Physician Insights offers in-depth analyses of the reasons behind treatment dynamics, prescribing behavior, and brand preference, enabling you to:

  • Understand the treatment landscape for a disease and how physicians make prescribing decisions.
  • Evaluate the drivers and obstacles that influence treatment selection.
  • Analyze your brand’s performance from the physician perspective to enhance or defend your competitive position.
  • Create impactful messaging for physicians by identifying brand differentiators and understanding what motivates prescribing behaviors.

Markets covered: United States

Primary research: Survey of 100 medical oncologists in the United States fielded in April 2025.

Key drugs: Cyramza, Enhertu, Herceptin, Keytruda, Lonsurf, Opdivo, Tevimbra, Vyloy, Yervoy

Related Market Assessment Reports

Report
Psoriasis – Geographic Focus: China – Psoriasis | China In-Depth | China | 2025
Psoriasis is a chronic dermatologic condition with rising prevalence in China, particularly in urban areas where heightened awareness and improved access to care have led to higher diagnosis rates…
Report
Ovarian Cancer – Landscape & Forecast – Disease Landscape & Forecast (G7)
The treatment landscape for ovarian cancer has been revolutionized by the angiogenesis inhibitor bevacizumab and the PARP inhibitors olaparib (Lynparza; AstraZeneca / Merck & Co.), niraparib (…
Report
Breast Cancer – Landscape & Forecast – Disease Landscape & Forecast (G7)
CDK4/6 inhibitors (Pfizer’s palbociclib, Novartis’s ribociclib, and Eli Lilly’s abemaciclib) combined with endocrine therapy are central to the treatment of metastatic HR-positive / HER2-…
Report
Type 2 Diabetes – Geographic Focus: China – Type 2 Diabetes – China In-Depth (China)
In China, type 2 diabetes (T2D) continues to be a leading public health concern, with the highest global prevalence. Biguanides continue to dominate the market, but the use of SGLT-2 inhibitors and…
Report
Chronic Kidney Disease – Geographic Focus: China – Chronic Kidney Disease – China In-Depth (China)
Chronic kidney disease (CKD) is an irreversible condition requiring lifelong management. In China, CKD is notably widespread, particularly among older adults and those with chronic risk factors…